Drug class in one race
PI3K-alpha (mutant-selective) drugs for HR+/HER2- Metastatic Breast Cancer
2 tracked PI3K-alpha (mutant-selective) drugs in the HR+/HER2- Metastatic Breast Cancer race. The class explanation lives on the PI3K-alpha (mutant-selective) page; the full indication pipeline across every mechanism is on the HR+/HER2- Metastatic Breast Cancer page.
2 Phase 3